Company Analysis
Sign in

Innate Pharma S.A. (IPHA)

Nasdaq: IPHA · Biological Products, (No Diagnostic Substances) · Marseille · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.3
◀ Past 5.9● Present 4.0▶ Future 3.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Innate Pharma S.A.

Nine metrics read from its own filings, by tense
Headline grade
4.3/10
◀ Past5.925% of the headline
● Present4.035% of the headline
▶ Future3.540% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.9/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.0/10

Has it survived what it has been through?

No warning events in its filings since 2017.

weight 22% of this tense · 80th percentile among 159 sector filers · read for itself

From the record

Innate Pharma S.A.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.4/10

What has it actually done, year after year?

-18% a year over 9 filed years; profitable in 1 of 9.

weight 45% of this tense · 34th percentile among 102 sector filers · read for its customers

From the record

Innate Pharma S.A.'s 9 filed years say what it did: revenue went from EUR 44 million in fiscal 2017 to EUR 9 million in fiscal 2025, down 18% a year; it rose in 3 of 8 years; the deepest fall was 90% from fiscal 2018 to fiscal 2025; net income was positive in 1 of 9 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-18.0%bottom 11% of its family
  • the share of years revenue rosebottom 21% of its family
  • the share of filed years with a profittop 31% of its family
  • the deepest fall from a revenue peak90.4%bottom 34% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
7.8/10

How has it treated the people who own it?

SI estimate 7.8/10, confidence 35 of 100 (one part).

weight 33% of this tense · 78th percentile among 146 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 22% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 146 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Innate Pharma S.A.'s shareholder treatment is put at 7.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 22% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.0/1035% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.8/10

Is it financially healthy right now?

Leverage 135%: owes 135¢ per asset dollar.

weight 45% of this tense · 38th percentile among 147 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Innate Pharma S.A.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 135 cents per dollar of assets, and net share issuance: its share count grew 10.5% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 13% of its family
  • the share count against the year beforetop 36% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
2.6/10

How strong is its position in its industry?

bottom 26% of 102 in its family; net margin -546.1%.

weight 22% of this tense · 26th percentile among 102 sector filers · read for its customers

From the record

Innate Pharma S.A.'s standing among 102 graded names in its industry family: revenue of EUR 9 million in fiscal 2025 is not ranked by size, since the family reports in another currency; a net margin of -546.1% ranks in the bottom 42%; revenue growth of -46.1% a year over the last 3 filed years ranks in the bottom 10% (its annual reports).

What it rests on

  • net margin-546.1%bottom 42% of its family
  • three-year revenue growth-46.1%bottom 10% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
5.0/10

What are the people in charge doing?

SI estimate 5.0/10, confidence 20 of 100 (family median).

weight 33% of this tense · 50th percentile among 130 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 130 members with one.
What the record cannot read
It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read.
How it was reasoned
family median, 130 readings behind it.
Confidence
20 of 100
What would change it
Its next annual report on file with the inputs replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Innate Pharma S.A.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; no officer or director has filed a Form 3, 4 or 5 for it in the last fifteen months, so the years in charge cannot be read, so the desk assumes the typical reading of its industry family, the median of 130 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

3.5/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
5.4/10

How much room does it have to grow?

top 46% of 92 in its family for room to expand.

weight 33% of this tense · 54th percentile among 92 sector filers · read for itself

From the record

Innate Pharma S.A.'s room to grow, from the newest filed statements (fiscal 2025): cash of EUR 28 million against no long-term debt tagged leaves 44.8% of its assets as net cash, top 35% of its family; cash from operations less capital spending is -587.4% of revenue (bottom 32%); research spending of 484.4% of revenue (top 35%) (its annual report).

What it rests on

  • cash less debt against assets44.8%top 35% of its family
  • cash from operations less capital spending against revenue-587.4%bottom 32% of its family
  • research spending against revenue484.4%top 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
2.8/10

What could actually drive growth from here?

bottom 27% of 100 in its family for growth drivers.

weight 45% of this tense · 27th percentile among 100 sector filers · read for its customers

From the record

Innate Pharma S.A.'s growth drivers, from the filed years to fiscal 2025: revenue grew -46.1% a year over the last three filed years against -18% over all 9, slowing (bottom 23% of its family); the newest year grew -55.3% (bottom 6%); research spending grew -5.5% a year (bottom 36%); capital spending grew -36% a year (bottom 45%) (its annual reports). Innate Pharma S.A. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-28.1 points a yearbottom 23% of its family
  • the newest year's revenue growth-55.3%bottom 6% of its family
  • three-year growth of research spending-5.5%bottom 36% of its family
  • three-year growth of capital spending-36.0%bottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
2.3/10

Did its newest year beat what its own record pointed to?

bottom 23% of 72 in its family for expectations against reality.

weight 22% of this tense · 23rd percentile among 72 sector filers · read for its shareholders

From the record

Innate Pharma S.A.'s newest year against its own record: revenue of EUR 9 million in fiscal 2025 came in 24.3% below the EUR 12 million its prior three years' pace pointed to (bottom 25% of its family); net income of EUR 49 million against a prior three-year average of EUR 38 million (bottom 26%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 17%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-24.3%bottom 25% of its family
  • net income against the prior three years' average-28%bottom 26% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 17% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton IPHA · research, not advice